Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs United Airlines Holdings Inc (UAL) Price & Performance

10X Genomics IncTrade
United Airlines Holdings IncTrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs United Airlines Holdings Inc — how do they compare? 10X Genomics Inc trades at $58.6 (market cap $7.64B), while United Airlines Holdings Inc trades at $126.9 (market cap $40.17B). The key difference: United Airlines Holdings Inc is far larger — about 5.3× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals.

TXGUAL
Market Cap
$7.64B$40.17B
Sector
HealthIndustrials
52-Week High
$58.57$136.11
52-Week Low
$11.34$85.21
Enterprise Value
$7.17B$57.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

United Airlines Holdings Inc

United Airlines (UAL) trades at $129.56, up 0.34% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $59.07B in 2025 and a net income margin of 5.56%, while valuation metrics like a P/E of 12.13 suggest potential undervaluation. Recent news highlights fleet innovation focus after merger attempts failed, with analyst consensus strongly bullish.

The outlook for UAL is positive, driven by sustained travel demand and cost management, but risks include fuel price volatility and competitive pressures. With 66% of analysts rating it Buy and a consensus price target of $167.73, the stock offers upside, though investors must monitor execution on fuel cost recapture and economic sensitivity.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG

About United Airlines Holdings Inc

United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.

Read more on UAL